368 related articles for article (PubMed ID: 32119801)
1. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation.
Lechner K; McKenzie AL; Kränkel N; Von Schacky C; Worm N; Nixdorff U; Lechner B; Scherr J; Weingärtner O; Krauss RM
Metab Syndr Relat Disord; 2020 May; 18(4):176-185. PubMed ID: 32119801
[TBL] [Abstract][Full Text] [Related]
2. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.
Neeland IJ; Ayers CR; Rohatgi AK; Turer AT; Berry JD; Das SR; Vega GL; Khera A; McGuire DK; Grundy SM; de Lemos JA
Obesity (Silver Spring); 2013 Sep; 21(9):E439-47. PubMed ID: 23687099
[TBL] [Abstract][Full Text] [Related]
3. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.
Holvoet P
Verh K Acad Geneeskd Belg; 2008; 70(3):193-219. PubMed ID: 18669160
[TBL] [Abstract][Full Text] [Related]
4. LIPID ACCUMULATION PRODUCT, VISCERAL ADIPOSITY INDEX, AND CHINESE VISCERAL ADIPOSITY INDEX AS MARKERS OF CARDIOMETABOLIC RISK IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: A CROSS-SECTIONAL STUDY.
Xie X; Li Q; Zhang L; Ren W
Endocr Pract; 2018 Jan; 24(1):33-39. PubMed ID: 29144802
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome: therapeutic considerations.
Grundy SM
Handb Exp Pharmacol; 2005; (170):107-33. PubMed ID: 16596797
[TBL] [Abstract][Full Text] [Related]
6. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
7. [Atherogenic dyslipidemia and residual risk. State of the art in 2014].
Millán Núñez-Cortés J; Pedro-Botet Montoya J; Pintó Sala X;
Clin Investig Arterioscler; 2014; 26(6):287-92. PubMed ID: 25450326
[TBL] [Abstract][Full Text] [Related]
8. High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study.
Quispe R; Michos ED; Martin SS; Puri R; Toth PP; Al Suwaidi J; Banach M; Virani SS; Blumenthal RS; Jones SR; Elshazly MB
J Am Heart Assoc; 2020 Feb; 9(3):e013600. PubMed ID: 32013698
[TBL] [Abstract][Full Text] [Related]
9. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report.
Jacobson TA; Ito MK; Maki KC; Orringer CE; Bays HE; Jones PH; McKenney JM; Grundy SM; Gill EA; Wild RA; Wilson DP; Brown WV
J Clin Lipidol; 2015; 9(2):129-69. PubMed ID: 25911072
[TBL] [Abstract][Full Text] [Related]
10. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia.
Oravec S; Dostal E; Dukát A; Gavorník P; Kucera M; Gruber K
Neuro Endocrinol Lett; 2011; 32(4):502-9. PubMed ID: 21876506
[TBL] [Abstract][Full Text] [Related]
11. The metabolic basis of atherogenic dyslipidemia.
Vinik AI
Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
[TBL] [Abstract][Full Text] [Related]
12. Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome.
Wittwer J; Bradley D
Front Immunol; 2021; 12():612496. PubMed ID: 33717095
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
[TBL] [Abstract][Full Text] [Related]
14. Plasma vitamin D and parathormone are associated with obesity and atherogenic dyslipidemia: a cross-sectional study.
Guasch A; Bulló M; Rabassa A; Bonada A; Del Castillo D; Sabench F; Salas-Salvadó J
Cardiovasc Diabetol; 2012 Dec; 11():149. PubMed ID: 23228198
[TBL] [Abstract][Full Text] [Related]
15. Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.
Bosomworth NJ
Can Fam Physician; 2013 Nov; 59(11):1169-80. PubMed ID: 24235189
[TBL] [Abstract][Full Text] [Related]
16. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception.
Plana N; Ibarretxe D; Cabré A; Ruiz E; Masana L
Clin Investig Arterioscler; 2014; 26(6):274-84. PubMed ID: 24931442
[TBL] [Abstract][Full Text] [Related]
19. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of the metabolic syndrome.
Ceska R
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S2-4. PubMed ID: 17935057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
